CDC & White House Warn of “Rhino Tranq” Found in Illicit Fentanyl Supply

In early April 2026, the Office of National Drug Control Policy, CDC Release Health Advisory on Medetomidine in Illicit Fentanyl, a coordinated health advisory from the Centers for Disease Control and Prevention (CDC) and the White House Office of National Drug Control Policy (ONDCP) highlighted a disturbing trend in the U.S. illegal drug supply: the increasing presence of medetomidine, a veterinary sedative sometimes termed “rhino tranq,” “mede,” or “dex.”

What Is Medetomidine and Why Does It Matter

Medetomidine is a powerful alpha-2 adrenergic agonist approved for sedation and pain relief in animals, predominantly dogs; it is not approved for human use. Its appearance in illegally manufactured fentanyl supplies poses serious health risks.

While illicit fentanyl remains at the heart of the current overdose epidemic, medetomidine is now being found in an increasing number of drug seizures, paraphernalia samples, and even wastewater testing, particularly in the Northeast and Midwest regions of the country.

According to the CDC’s latest situation summary, detections of medetomidine increased dramatically from just 247 reports in 2023 to over 8,000 in 2025.

Health Risks: Sedation, Overdose, and Severe Withdrawal

Medetomidine’s effects are medically distinct from opioids, and its presence in the drug supply complicates both clinical care and harm reduction:

• Profound Sedation & Cardiovascular Effects: The drug can cause extreme sedation, dangerously slow heart rate (bradycardia), and low blood pressure (hypotension).
• Overdose Complexity: Because medetomidine isn’t an opioid, traditional overdose reversal with naloxone may not fully counter its effects, even though naloxone should still be administered when fentanyl is suspected.
• Withdrawal Syndrome: Regular exposure to medetomidine can lead to a severe withdrawal state when someone stops taking it. Symptoms include rapid heart rate (tachycardia), severe hypertension, fluctuating alertness, chest pain, intractable nausea, and vomiting, conditions that often require emergency or intensive care.

This withdrawal profile is unusually intense and more complex than typical opioid withdrawal, making clinical recognition and management challenging.

What the CDC & ONDCP Are Advising

The advisory issued through the CDC’s Health Alert Network is directed at public health officials, clinicians, laboratory professionals, and people at risk of overdose, emphasizing that medetomidine:

• It is increasingly present in the illegal drug supply, frequently mixed with illicit fentanyl.
• May not be detected by standard toxicology screens, requiring heightened clinical suspicion.
• It can cause prolonged sedation that does not reverse easily with naloxone alone.
• Requires collaborative surveillance between public health and safety agencies to monitor shifts in drug supply trends.

Health departments and clinicians are encouraged to use syndromic surveillance and real-time toxicology to identify medetomidine involvement in overdoses or severe withdrawal.

Implications for Addiction Treatment and Harm Reduction

For addiction professionals and harm reduction advocates, the medetomidine warning underscores several critical points:

1. Polysubstance Risk Continues to Grow: Fentanyl is no longer acting alone in the illicit market. Modifications to drug cocktails, like adding medetomidine, complicate detection and response.
2. Awareness & Training: Clinicians, emergency responders, and treatment providers must be educated about atypical overdose presentations and withdrawal patterns that may not respond to traditional opioid-focused treatments.
3. Harm Reduction Tools: Although test strips are more widely available for fentanyl and xylazine, access to reliable medetomidine detection tools is limited, making personal risk reduction efforts harder.

What To Take Away From This

The CDC’s alert, reinforced by the ONDCP’s public statement, is a stark reminder that the illicit drug landscape is continually evolving, with new adulterants emerging that increase both overdose risk and treatment complexity. For individuals, families, and communities affected by addiction, this development emphasizes that no illegal drug use is risk-free and that tailored clinical care and public health responses are essential in confronting a shifting overdose crisis.